Compare Dishman Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PANACEA BIOTECH - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PANACEA BIOTECH DISHMAN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 8.9 282.4% View Chart
P/BV x 3.3 3.5 96.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PANACEA BIOTECH
Mar-19
DISHMAN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs374354 105.9%   
Low Rs129138 93.3%   
Sales per share (Unadj.) Rs197.874.6 265.3%  
Earnings per share (Unadj.) Rs21.26.7 317.5%  
Cash flow per share (Unadj.) Rs34.715.5 224.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.957.2 314.5%  
Shares outstanding (eoy) m80.6961.25 131.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.3 38.6%   
Avg P/E ratio x11.936.8 32.2%  
P/CF ratio (eoy) x7.215.9 45.7%  
Price / Book Value ratio x1.44.3 32.5%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30615,061 134.8%   
No. of employees `0000.82.3 35.8%   
Total wages/salary Rs m5,3551,471 364.1%   
Avg. sales/employee Rs Th19,252.71,973.6 975.5%   
Avg. wages/employee Rs Th6,459.5635.6 1,016.3%   
Avg. net profit/employee Rs Th2,064.1176.8 1,167.5%   
INCOME DATA
Net Sales Rs m15,9614,567 349.5%  
Other income Rs m26545 592.4%   
Total revenues Rs m16,2264,612 351.8%   
Gross profit Rs m4,1032,030 202.2%  
Depreciation Rs m1,091540 202.0%   
Interest Rs m9441,048 90.1%   
Profit before tax Rs m2,334486 480.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62477 808.8%   
Profit after tax Rs m1,711409 418.3%  
Gross profit margin %25.744.4 57.8%  
Effective tax rate %26.715.9 168.5%   
Net profit margin %10.79.0 119.7%  
BALANCE SHEET DATA
Current assets Rs m11,0182,415 456.3%   
Current liabilities Rs m9,5179,077 104.8%   
Net working cap to sales %9.4-145.9 -6.4%  
Current ratio x1.20.3 435.2%  
Inventory Days Days11065 169.8%  
Debtors Days Days3571 49.1%  
Net fixed assets Rs m16,3048,333 195.7%   
Share capital Rs m16161 263.3%   
"Free" reserves Rs m12,9073,443 374.9%   
Net worth Rs m14,5163,504 414.3%   
Long term debt Rs m4,189461 908.4%   
Total assets Rs m29,80513,755 216.7%  
Interest coverage x3.51.5 237.1%   
Debt to equity ratio x0.30.1 219.3%  
Sales to assets ratio x0.50.3 161.3%   
Return on assets %8.910.6 84.1%  
Return on equity %11.811.7 101.0%  
Return on capital %17.538.7 45.3%  
Exports to sales %24.820.9 118.7%   
Imports to sales %3.78.1 45.9%   
Exports (fob) Rs m3,956954 414.7%   
Imports (cif) Rs m596372 160.3%   
Fx inflow Rs m4,9521,203 411.6%   
Fx outflow Rs m697467 149.3%   
Net fx Rs m4,255736 577.8%   
CASH FLOW
From Operations Rs m2,7861,049 265.7%  
From Investments Rs m-1,529-54 2,857.8%  
From Financial Activity Rs m-941-1,011 93.0%  
Net Cashflow Rs m316-20 -1,606.1%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 12.7 1.3 976.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.6 93.6%  
Shareholders   46,261 10,259 450.9%  
Pledged promoter(s) holding % 35.8 35.1 102.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TORRENT PHARMA  NATCO PHARMA  CADILA HEALTHCARE  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS